Hancock Jaffe shares rise after IDE approval to begin venovalve U.S. pivotal trial

Stock Information for Hancock Jaffe

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Hancock Jaffe

enVVeno Medical Corporation Successfully Completes Rebranding
Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann
Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs
Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021
Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules
Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting
FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve
Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.